TCRT Stock Spikes On Heavy Volume As Traders Hunt Volatility

Alaunos Therapeutics Inc. stocks have been trading up by 40.62 percent amid heightened optimism over its cancer therapy pipeline advancements.

Live Update At 08:32:05 EDT: On Friday, September 18, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 40.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Alaunos Therapeutics Inc., trading under ticker TCRT, looks like a classic high-risk biotech from the numbers alone. Revenue is only about $5,000, with a brutal pretax profit margin around -3,347%. In plain English, every $1 TCRT brings in is swamped by huge operating losses. That is the definition of a speculative ticker.

The balance sheet shows total assets of roughly $1.5M and equity of about $652,000. Cash is only $124,000 at the end of the reported quarter, while working capital sits at about -$198,000. TCRT has no long-term debt on the books, but it still leans on short-term financing and payables, which pressure liquidity.

For traders, the key is the burn rate. Operating cash flow for Alaunos Therapeutics Inc. in the quarter was about -$300,000. That means TCRT is chewing through cash faster than it’s coming in, and the current ratio of 0.8 plus a quick ratio of 0.1 confirm the squeeze. These data points tell traders to expect ongoing financing needs and potential dilution as a recurring theme around TCRT.

Why Traders Are Watching TCRT Price Action

TCRT is lighting up screens because the chart shows exactly what short-term traders love: volatility and range. On the daily chart, Alaunos Therapeutics Inc. pulled back from late-August closes near $1.79–$1.79 down to a recent low around $1.28 on 2026/09/16. That’s a big percentage slide in just a couple of weeks. The very next day, TCRT bounced hard, closing near $1.60 after tagging $1.65 intraday. That bounce off the $1.28 area sets up a clear support zone for traders.

The intraday 5-minute data shows how aggressive the move has been. Early in the premarket, TCRT traded around $1.88–$2.00, then ripped through $2.50 and briefly touched above $3.10 before pulling back into the mid-$2s. That’s a huge range in a few hours. Alaunos Therapeutics Inc. is clearly attracting day traders who look for quick moves and tight risk control.

From a technical standpoint, TCRT has shifted from a slow grind lower on the daily chart to a momentum spike intraday. Traders will focus on whether Alaunos Therapeutics Inc. can hold above former resistance zones around $2.00–$2.20 and then $2.50. If TCRT stays above those levels, many momentum traders will keep it on watch for potential continuation. If it fails and slips back under $2.00, the chart tells a different story and short-biased traders will step in.

Conclusion

Alaunos Therapeutics Inc. is not a fundamentals-friendly story right now. TCRT has minimal revenue, heavy operating losses, and a thin cash position. The valuation metrics – like a sky-high price-to-sales ratio north of 1,500 and negative returns on assets and equity – underline how much this ticker depends on future hopes rather than present earnings. That’s typical in micro-cap biotech, but it also means TCRT is firmly in speculative territory.

For active traders, the opportunity is in the chart, not the balance sheet. TCRT is showing the classic pattern of a beaten-down biotech catching a wave of momentum. The violent premarket spike from sub-$2 to over $3 and back into the mid-$2s gives Alaunos Therapeutics Inc. a wide range to trade against. Short-term players will be mapping levels around $1.60, $2.00, $2.50, and that premarket high near $3.10.

Risk management is critical here. With liquidity pressures and ongoing cash burn, TCRT is the type of name that can offer big percentage swings both directions in a single session. As Tim Sykes likes to say, “The pattern is your edge, but only if you respect your stop and size small.” As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.”. Traders studying Alaunos Therapeutics Inc. should focus on clean setups, clear levels, and fast execution, treating TCRT as a trading vehicle, not a long-term commitment.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks